SGIOY - FDA OK's Janssen's HIV drug combo Cabenuva

The FDA has approved Johnson & Johnson (JNJ) unit, Janssen Pharmaceuticals' Cabenuva (consisting of Janssen's rilpivirine and ViiV Healthcare's cabotegravir), the first and only once-monthly, long-acting regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults.The complete regimen combines rilpivirine, a non-nucleoside reverse transcriptase inhibitor, with the integrase strand transfer inhibitor cabotegravir. Cabenuva, a co-packaged kit with two injectable medicines, offers people living with HIV a new approach for maintaining viral suppression.ViiV Healthcare is the HIV-focused joint venture between GlaxoSmithKline (GSK), Pfizer (PFE) and Shionogi (SGIOY).

For further details see:

FDA OK's Janssen's HIV drug combo Cabenuva